Verana Health Launches First End-to-End Urologic-Oncology Datasets

Event summary

  • Verana Health introduced new urologic-oncology datasets for bladder and prostate cancer research on February 19, 2026.
  • Datasets provide longitudinal insights into disease detection, treatment, and outcomes, bridging gaps between urology and medical oncology.
  • Powered by the COTA merger, datasets integrate data from over 30 Academic Medical Centers and 10 million oncology patients.
  • Bladder cancer dataset includes T-stage, tumor focality, tumor grade, and tumor response data.
  • Prostate cancer dataset tracks transitions between urology, radiation oncology, and medical oncology.

The big picture

Verana Health's new datasets address critical gaps in understanding patient journeys across urology and medical oncology, a growing challenge as genitourinary cancer incidences rise. The launch coincides with the ASCO Genitourinary Cancers Symposium, highlighting the industry's focus on cutting-edge research and treatment best practices. With exclusive access to large patient data sources, Verana Health is positioning itself as a key player in real-world evidence generation for oncology research.

What we're watching

Data Integration
How Verana Health will leverage the COTA merger to expand its dataset offerings across other specialties.
Regulatory Impact
Whether the comprehensive datasets will accelerate regulatory submissions for new urologic cancer treatments.
Market Adoption
The pace at which life sciences organizations adopt these datasets for evidence generation and commercialization decisions.